Streetwise Reports' Article Archives — August 2018 back to current month (14)
Drug Company Receives $5 Million Milestone Payment (08/31/2018)
Company entitled to receive quarterly earn-out payments from patent agreement.
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development.
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates.
An analyst discussed the implications to this firm of a competitive product's advancement.
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available.
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company.
The development of analytic methods is a key milestone in the development of water-soluble cannabis technology.
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent.
A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence.
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst.
An H.C. Wainwright & Co. report reviewed the arrangement.
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system.
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts.
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|